Insider Selling: Liquidia (NASDAQ:LQDA) Insider Sells $2,269,392.56 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Rajeev Saggar sold 29,534 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $76.84, for a total transaction of $2,269,392.56. Following the sale, the insider directly owned 142,265 shares in the company, valued at $10,931,642.60. This trade represents a 17.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Rajeev Saggar also recently made the following trade(s):

• On Wednesday, August 19th, Rajeev Saggar sold 50,000 shares of Liquidia stock. The shares were sold at an average price of $74.06, for a total transaction of $3,703,000.00.
• On Monday, July 13th, Rajeev Saggar sold 9,926 shares of Liquidia stock. The stock was sold at an average price of $71.51, for a total transaction of $709,808.26.

Liquidia Stock Performance

LQDA stock opened at $68.62 on Friday. The company has a 50 day moving average price of $79.29 and a 200 day moving average price of $56.21. Liquidia Corporation has a fifty-two week low of $21.15 and a fifty-two week high of $93.61. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.31 and a quick ratio of 2.12. The stock has a market capitalization of $6.14 billion, a PE ratio of 50.09 and a beta of 0.58.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Wednesday, August 12th. The company reported $0.74 EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). The firm had revenue of $171.68 million during the quarter, compared to the consensus estimate of $168.48 million. Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The firm’s quarterly revenue was up 1842.1% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.49) earnings per share. Analysts forecast that Liquidia Corporation will post 2.57 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LQDA. GSA Capital Partners LLP grew its stake in shares of Liquidia by 63.6% during the fourth quarter. GSA Capital Partners LLP now owns 63,176 shares of the company’s stock worth $2,179,000 after purchasing an additional 24,555 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Liquidia by 63.3% in the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock valued at $2,199,000 after purchasing an additional 22,592 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in Liquidia in the fourth quarter valued at about $709,000. WCG Wealth Advisors LLC lifted its stake in Liquidia by 98.2% in the fourth quarter. WCG Wealth Advisors LLC now owns 54,411 shares of the company’s stock valued at $1,877,000 after buying an additional 26,957 shares during the period. Finally, Handelsbanken Fonder AB bought a new position in Liquidia during the second quarter worth about $1,993,000. 64.54% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Piper Sandler set a $129.00 price target on Liquidia in a report on Friday, July 24th. Bank of America lifted their price objective on Liquidia from $79.00 to $92.00 and gave the stock a “neutral” rating in a research report on Thursday, August 13th. Royal Bank Of Canada set a $130.00 price objective on Liquidia in a report on Friday, July 24th. Raymond James Financial restated a “strong-buy” rating and set a $106.00 target price on shares of Liquidia in a research report on Thursday, August 13th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $98.08.

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).